RB 6145
Alternative Names: PD 144872Latest Information Update: 21 Aug 2019
At a glance
- Originator BTG; Nonindustrial source; Pfizer
- Developer BTG; Nonindustrial source
- Class Antineoplastics; Nitroimidazoles; Radiosensitisers; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 31 Aug 1999 No-Development-Reported for Cancer in United Kingdom (Unknown route)